Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ilanna Loeffel"'
Autor:
Yi He, Salvador Alejo, Prabhakar Pitta Venkata, Jessica D. Johnson, Ilanna Loeffel, Uday P. Pratap, Yi Zou, Zhao Lai, Rajeshwar R. Tekmal, Edward R. Kost, Gangadhara R. Sareddy
Publikováno v:
International Journal of Molecular Sciences; Volume 23; Issue 13; Pages: 7159
Ovarian cancer (OCa) is the deadliest gynecologic cancer. Emerging studies suggest ovarian cancer stem cells (OCSCs) contribute to chemotherapy resistance and tumor relapse. Recent studies demonstrated estrogen receptor beta (ERβ) exerts tumor suppr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c03b0f54cbfffa10d980dfae9fd6e6f
https://pubmed.ncbi.nlm.nih.gov/35806169
https://pubmed.ncbi.nlm.nih.gov/35806169
Autor:
Takayoshi Suzuki, Gabrielle Gray, Rajeshwar Rao Tekmal, Yi He, Srinath Palakurthi, Sureshkumar Mulampurath Achuthan Pillai, Prabhakar Pitta Venkata, Zhao Lai, Junhao Liu, Edward R. Kost, Salvador Alejo, Suryavathi Viswanadhapalli, Ilanna Loeffel, Gangadhara R. Sareddy, Yi Zou, Bridgitte E. Palacios, Ratna K. Vadlamudi, Uday P. Pratap, Yihong Chen
Publikováno v:
Cancer letters. 524
Endometrial cancer (EC) often exhibit aberrant activation of PI3K/Akt/mTOR signaling and targeted therapies using mTOR inhibitors showed limited success. The epigenetic modifier, lysine-specific histone demethylase-1A (KDM1A/LSD1) is overexpressed in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70ad2d9424beea8ece843b299524d4ec
https://pubmed.ncbi.nlm.nih.gov/34673129
https://pubmed.ncbi.nlm.nih.gov/34673129
Autor:
Yi He, Salvador Alejo, Prabhakar P. Venkata, Jessica D. Johnson, Ilanna Loeffel, Julie Ann Martel, Uday P. Pratap, Suryavathi Viswanadhapalli, Rajeshwar R. Tekmal, Ratna K. Vadlamudi, Edward Kost, Gangadhara R. Sareddy
Publikováno v:
Cancer Research. 82:891-891
Background: Ovarian cancer (OCa) is the deadliest gynecologic cancer. Emerging studies suggest that ovarian cancer stem cells (OCSCs) contribute to tumor relapse and chemotherapy resistance. Recent studies demonstrate that OCa cells express estrogen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::896b2377dbfd73af85abaf11d84aede7
https://doi.org/10.1158/1538-7445.am2022-891
https://doi.org/10.1158/1538-7445.am2022-891
Autor:
Bridgitte E. Palacios, Salvador Alejo, Yi He, Takayoshi Suzuki, Kristin A. Altwegg, Gangadhara R. Sareddy, Uday P. Pratap, Rajeshwar Rao Tekmal, Edward R. Kost, Suryavathi Viswanadhapalli, Yihong Chen, Prabhakar Pitta Venkata, Ilanna Loeffel
Publikováno v:
Cancer Research. 80:1764-1764
Background: Ovarian cancer (OCa) is the deadliest gynecologic cancer. Recent studies suggest that OCa cells express estrogen receptor beta (ESR2), which functions as a tumor suppressor. However, ESR2 expression decreases during tumor progression and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1cdaa4f6450b63ea559abd7c92c6ef03
https://doi.org/10.1158/1538-7445.am2020-1764
https://doi.org/10.1158/1538-7445.am2020-1764